Evidence map›Paper›PMID 12454289›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2002

Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion.

Michael J Pinkoski, Nathalie M Droin, Tesu Lin, Laurent Genestier, Thomas A Ferguson, Douglas R Green

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michael J PinkoskiDivision of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA. michael@liai.org
Nathalie M Droin
Tesu Lin
Laurent Genestier
Thomas A Ferguson
Douglas R Green
La Jolla Institute for Immunology · US

Funding

Survival Function of the Fadd-Caspase-8-Flip ComplexR01AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 1999 to 2016
$6.3M
Survival Function of the Fadd-Caspase-8-Flip Complex - MERIT ExtensionR37AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Douglas R. Green · 2017 to 2026
$4.5M
NIAID NIH HHS AI44828-02NIAID NIH HHS R01 AI044828NIAID NIH HHS R37 AI044828
6 · The paper itself

Abstract

Peripheral lymphocyte deletion is required for reduction of lymphocyte numbers after expansion in response to antigen. Peripheral deletion is mediated in part by the activation of apoptosis by engagement of the death receptor, Fas (CD95), by its ligand, Fas ligand (FasL; CD95L), among other mechanisms. Here we used T cell receptor (TCR) transgenic animals to examine the role of inducible expression of nonlymphoid FasL in response to peptide antigen. Antigenic challenge of TCR transgenic mice resulted in increased expression of FasL in a number of nonlymphoid tissues including the epithelium of the small intestine. Similar results were obtained in an adoptive transfer system in which TCR transgenic T cells were transferred into recipient animals. The functional relevance of nonlymphoid FasL in peripheral deletion is supported by the observation that FasL-deficient gld animals showed a significantly reduced rate of clearance of transferred antigen-specific lymphocytes, although the lymphocytes themselves were wild type for FasL. These observations were supported further by studies in a transgenic mouse model where lacZ was expressed under the control of the proximal promoter of the FasL gene. Using these transgenic mice, we observed induced activity of the FasL promoter in intestinal epithelial cells throughout the crypts and villi, where we also observed infiltration of activated T cells. These data demonstrate that nonlymphoid FasL is expressed in response to peripheral T cell activation and participates in the regulation of T cells that infiltrate peripheral tissues.

Indexed as

Adoptive TransferAnimalsAntigens, BacterialApoptosisEnterotoxinsFas Ligand ProteinGenes, ReporterHumansIntestinal MucosaLac OperonLymphocyte ActivationMembrane GlycoproteinsMiceMice, Inbred BALB CMice, Inbred C57BLMice, Mutant StrainsAntigens, Bacterialenterotoxin B, staphylococcalEnterotoxinsFASLG protein, humanFas Ligand ProteinFasl protein, mouseMembrane GlycoproteinsOvalbuminReceptors, Antigen, T-CellRecombinant Fusion ProteinsSuperantigens

Identifiers

PMID12454289
PMCPMC138584
OpenAlexW2169113127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.